Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.

Molecular cancer·2026
Same author

Decoy oligonucleotide technology in cancer therapy: molecular mechanisms, challenges, and translational potential.

Medical oncology (Northwood, London, England)·2026
Same author

NLRP3 inflammasome as a central target for the pleiotropic effects of GLP-1 receptor agonists.

International immunopharmacology·2026
Same author

Effect of cyclodextrins on cardiometabolic indices: a systematic review and meta-analysis of randomized controlled trials.

Journal of diabetes and metabolic disorders·2026
Same author

Mechanistic interactions between curcumin and statins: pharmacological convergence and therapeutic implications.

Molecular biology reports·2026
Same author

Exploring the Potential of Calebin-A in Targeting Obesity-Related Genes and Pathways.

Journal of cellular and molecular medicine·2026

Related Experiment Video

Updated: Mar 25, 2026

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma
11:02

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma

Published on: August 9, 2022

3.6K

Dendrimer technologies for brain tumor.

Vijay Mishra1, Prashant Kesharwani2

  • 1Pharmaceutical Nanotechnology Research Laboratory, Adina Institute of Pharmaceutical Sciences, Sagar, M.P. 470002, India.

Drug Discovery Today
|February 20, 2016
PubMed
Summary
This summary is machine-generated.

Surface-engineered dendrimers offer a promising strategy to overcome the blood-brain barrier (BBB) challenge for brain tumor treatment. These advanced nanomaterials facilitate drug delivery across the BBB, enhancing therapeutic potential for brain cancers.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.5K

Related Experiment Videos

Last Updated: Mar 25, 2026

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma
11:02

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma

Published on: August 9, 2022

3.6K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.5K

Area of Science:

  • Nanotechnology in Medicine
  • Oncology
  • Neuroscience

Background:

  • Brain tumors, though rare, are highly lethal cancers.
  • The blood-brain barrier (BBB) severely restricts drug entry into the central nervous system, posing a major challenge for brain tumor therapeutics.
  • Developing effective treatments requires strategies to bypass or overcome the BBB.

Purpose of the Study:

  • To review the role of dendrimers in overcoming the BBB for brain tumor treatment.
  • To explore recent research, opportunities, and challenges in dendrimer-based brain tumor therapeutics.
  • To highlight how surface-engineered dendrimers can improve drug delivery and targeting for central nervous system cancers.

Main Methods:

  • Review of existing literature on brain tumors, the BBB, and dendrimer applications.
  • Analysis of surface-engineered dendrimers for biocompatibility, drug release, and BBB targeting.
  • Examination of strategies for transporting anticancer agents across the BBB using dendrimers.

Main Results:

  • Surface-engineered dendrimers demonstrate enhanced biocompatibility and drug-release kinetics.
  • Dendrimers show potential for targeting both the BBB and brain tumors.
  • These nanomaterials facilitate the transport of anticancer bioactives across the BBB.

Conclusions:

  • Dendrimer-based therapeutics represent a promising avenue for treating brain tumors.
  • Further research is needed to address challenges and optimize dendrimer design for clinical application.
  • Surface modification of dendrimers is key to improving their efficacy in crossing the BBB and delivering drugs to brain tumors.